Early access
Sign in
Taking people in GermanyPhase 3

AZD6234 compared with placebo in adults with type 2 diabetes and overweight or obesity

Tests AZD6234 against placebo for weight change in adults with type 2 diabetes.

Key facts

Who runs it
AstraZeneca AB
Where
Berlin, Bochum, Bünde, Dresden, Frankfurt am Main, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Hamburg, Hanover, Homburg, Jerichow, Karlsruhe, Leipzig, Magdeburg, Mainz, München, Offenbach Am Main, and Schwerin, GermanySee the 22 sitesAlso in 3 other countries, 35 sites
Registry title
A Study to evaluate effect of AZD6234 in adult participants with Type 2 Diabetes Mellitus and obesity or overweight
Status
Recruiting
Phase
Phase 3
People taking part
420 people, planned
Started
26 Oct 2026
Expected to end
9 Aug 2028
Type of study
Interventional
Record updated
9 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who are also overweight or have obesity. It compares AZD6234 with a placebo.

Age
18 years or older
Sex
Men and women
Disease stage
Type 2 diabetes diagnosed at least 90 days before screening, with BMI of 27 kg/m2 or more. HbA1c at screening of 6.0% (42 mmol/mol) to 10% (86 mmol/mol), managed with diet and exercise alone or with a stable dose of an oral glucose-lowering medicine.
Earlier treatment
Must not have used a GLP-1 receptor agonist or GLP-1 medicine in the 3 months before randomisation. Must not have used insulin for type 2 diabetes in the 3 months before screening. Must have tried at least once, without success, to lose weight.
Biomarker or test result
HbA1c of 6.0% (42 mmol/mol) to 10% (86 mmol/mol) at screening.

Main reasons for not taking part

  • Obesity mainly caused by other hormone disorders
  • Type 1 diabetes or diabetes that is not clearly type 2
  • Ketoacidosis or hyperosmolar coma in the 3 months before screening
  • Significant liver or bile duct disease, or high liver test results at screening
  • Weight change of more than 5% in the 3 months before randomisation

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Males & females ≥ 18 years of age
  • BMI ≥ 27 kg/m2
  • Diagnosed with T2DM ≥ 90 days prior to Screening
  • HbA1c value at Screening of ≥ 6.0% (42 mmol/mol) and ≤ 10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling)
  • Stable body weight (≤ 5% body weight change) for at least 3 months prior to Randomisation
  • History of at least one self-reported unsuccessful attempt to lose body weight in lifetime

Who cannot take part

  • Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening
  • Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation
  • Use of insulin therapy for T2DM within 3 months prior to screening
  • Obesity primarily caused by other endocrine disorders
  • Significant hepatobiliary disease and/or any of the following results at Screening: - ALT ≥ 3.0 X ULN - AST ≥ 3.0 X ULN - TBL > 1.5 X ULN (except for cases of known Gilbert’s Syndrome)

Where in Germany

Also in 3 other countries, 35 sites

  • FutureMeds GmbHBerlin, GermanyTaking people
  • Klinische Forschung Berlin-Mitte GmbHBerlin, GermanyTaking people
  • Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil gGmbHBochum, GermanyTaking people
  • Internistische GemeinschaftspraxisBünde, GermanyTaking people
  • Klinische Forschung Dresden GmbHDresden, GermanyTaking people
  • ClinPhenomics CVC GmbHFrankfurt am Main, GermanyTaking people
  • IKF Pneumologie GmbH & Co. KGFrankfurt am Main, GermanyTaking people
  • Universitaetsklinikum Frankfurt AöRFrankfurt Am Main, GermanyTaking people
  • Medical Center- University of FreiburgFreiburg im Breisgau, GermanyTaking people
  • Universitaetsmedizin GoettingenGoettingen, GermanyTaking people
  • Klinische Forschung Hamburg GmbHHamburg, GermanyTaking people
  • Velocity Clinical Research Germany GmbHHamburg, GermanyTaking people
  • Klinische Forschung Hannover-Mitte GmbHHanover, GermanyTaking people
  • Universitaetsklinikum des Saarlandes AöRHomburg, GermanyTaking people
  • Praxisgemeinschaft JerichowJerichow, GermanyTaking people
  • Klinische Forschung Karlsruhe GmbHKarlsruhe, GermanyTaking people
  • Velocity Clinical Research Germany GmbHLeipzig, GermanyTaking people
  • Institut Fuer Praeventive Medizin & Klinische Forschung GbRMagdeburg, GermanyTaking people
  • IKF Pneumologie GmbH & Co. KGMainz, GermanyTaking people
  • Hausarztpraxis am HeimeranplatzMünchen, GermanyTaking people
  • FutureMeds GmbHOffenbach Am Main, GermanyTaking people
  • Klinische Forschung Schwerin GmbHSchwerin, GermanyTaking people

About the trial

What the trial wants to find out

To evaluate the effect of AZD6234 as compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Type 2 Diabetes Mellitus and Obesity or Overweight
Plain-language title
AZD6234 compared with placebo in adults with type 2 diabetes and overweight or obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
9 October 2026